Rafal Leszek Pawlinski

US Patent:

20090022729, Jan 22, 2009

Filed:

Apr 11, 2008

Appl. No.:

12/101638

Inventors:

Nigel Mackman - Chapel Hill NC, US
Rafal Pawlinski - Chapel Hill NC, US
Burns C. Blaxall - Pittsford NY, US

International Classification:

A61K 39/395
A61K 38/02
A61K 31/7088
A61K 48/00
A61K 38/05
A61K 31/426
A61K 31/17
A61K 31/4453
A61K 31/55
A61K 31/538
A61K 31/519
A61K 38/08
A61K 31/4184
A61K 38/10
C12N 5/06

US Classification:

4241431, 4241301, 514 2, 514 44, 514 19, 514369, 514597, 514326, 5142171, 5142305, 514267, 514388, 514 16, 514 14, 514 17, 435375

Abstract:

The present invention provides methods and pharmaceutical compositions for treating or preventing cardiac dysfunctions (e.g., cardiac hypertrophy, cardiac remodeling, or heart failure) in subjects who have or are likely to develop cardiomyopathies. Some of the methods are directed to therapeutic or prophylactic treatment of cardiac dysfunctions in subjects having undergone myocardial injuries such as cardiac ischemia/reperfusion or myocardial infarction. Typically, these methods comprising administering to the subjects a therapeutic composition comprising a compound which can specifically inhibit PAR1 mediated signaling or down-regulate the cellular level of PAR1.

US Patent:

20220265699, Aug 25, 2022

Filed:

May 13, 2022

Appl. No.:

17/744407

Inventors:

- Chapel Hill NC, US
Jian Liu - Chapel Hill NC, US
Rafal Pawlinski - Chapel Hill NC, US
Brian Cooley - Chapel Hill NC, US

International Classification:

A61K 31/727
A61P 1/16
A61P 7/02

Abstract:

Disclosed is a method of treating liver ischemia reperfusion (I/R) injury in a subject. In some aspects, the method comprises providing a subject suffering from liver I/R injury or at risk of suffering liver I/R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some aspects, the one or more HS compounds comprises about 5 to about 18 saccharide units, optionally about 12 to about 18 saccharide units. In some aspects, the one or more HS compounds comprises about 12 saccharide units.

US Patent:

20210260098, Aug 26, 2021

Filed:

Jun 19, 2019

Appl. No.:

17/254145

Inventors:

- Chapel Hill NC, US
Jine Li - Chapel Hill NC, US
Guowei Su - Chapel Hill NC, US
Rafal Pawlinski - Chapel Hill NC, US
Erica Sparkenbaugh - Chapel Hill NC, US

International Classification:

A61K 31/737
A61P 39/02

Abstract:

Chondroitin sulfate compounds comprising chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, C8 backbone 13 mer, C8-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof are provided. Methods of treating histone toxicity in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the histone toxicity in the subject. Pharmaceutical compositions for use in treating histone toxicity and/or sepsis are provided. Methods of treating sepsis in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the sepsis in the subject.